Psyched: Psychedelics & Sex, MDMA And Federal Approval, Canadians For End-Of-Life Care And More
Portfolio Pulse from Lara Goldstein
A new study highlights the potential of psychedelics like LSD and magic mushrooms in improving sexual function. The FDA has accepted an NDA from Lykos Therapeutics for MDMA-assisted therapy for PTSD, marking a significant step towards integrating psychedelic therapies into mainstream medicine. Despite the growing interest and decriminalization efforts in several states, federal law still prohibits psilocybin. Canadian research supports psilocybin therapy for end-of-life distress, and a Washington doctor is challenging the DEA for approval to use it with terminally ill patients. The psychedelics sector, including companies like Numinus Wellness and various psychedelics stocks, shows signs of growth and investor interest.
February 15, 2024 | 1:36 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
AdvisorShares Psychedelics ETF (PSIL) shows steady performance with slight fluctuations, indicating stable investor interest in the psychedelics sector.
PSIL's performance reflects the current state of the psychedelics market, with steady interest but minor fluctuations suggesting a neutral short-term impact on its stock price.
CONFIDENCE 85
IMPORTANCE 60
RELEVANCE 90
POSITIVE IMPACT
COMPASS Pathways closes at $10.33, showing resilience and potential for growth amidst the evolving psychedelics landscape.
COMPASS Pathways' closing price indicates a positive trend and resilience in the market, suggesting potential for short-term growth as interest in psychedelic therapies increases.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 80
POSITIVE IMPACT
GH Research continues its upward trend, closing at $8.04, reflecting growing investor confidence in its psychedelic therapy research.
GH Research's sustained upward trend in stock price is indicative of increasing investor confidence in its research and potential in the psychedelics market, suggesting a positive short-term outlook.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Mind Medicine (MindMed) closes at $4.40, showing a positive uptick and potential for further growth in the psychedelics sector.
Mind Medicine's closing price reflects a positive trend and investor interest in its psychedelic therapy research, suggesting potential for short-term growth.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Numinus Wellness backed by MAPS, Eight Capital, and Integrated V.C. in a $6M offering, indicating strong investor confidence and potential for growth.
The financial backing from notable entities suggests a positive outlook on Numinus Wellness's future, potentially leading to increased investor interest and stock price appreciation in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80